ACADIA Pharmaceuticals Inc. ACAD
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.85% | 16.40% | 9.72% | 9.39% | 11.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.85% | 16.40% | 9.72% | 9.39% | 11.27% |
| Cost of Revenue | 1.73% | 11.34% | 3.04% | -9.43% | 28.10% |
| Gross Profit | 36.51% | 19.42% | 14.24% | 26.22% | 2.56% |
| SG&A Expenses | 19.34% | 20.03% | 35.33% | 19.63% | 0.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.40% | 16.34% | 21.18% | 5.54% | 11.03% |
| Operating Income | 100.58% | 16.87% | -123.93% | 148.87% | 12.99% |
| Income Before Tax | 80.38% | 15.57% | -85.67% | -83.66% | 14.92% |
| Income Tax Expenses | 199.01% | 10.54% | -96.09% | -1,525.64% | -549.99% |
| Earnings from Continuing Operations | -25.43% | 18.13% | -80.84% | 90.32% | 119.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.43% | 18.13% | -80.84% | 90.32% | 119.07% |
| EBIT | 100.58% | 16.87% | -123.93% | 148.87% | 12.99% |
| EBITDA | 94.73% | 16.10% | -107.30% | 66.49% | 13.13% |
| EPS Basic | -27.03% | 15.54% | -81.28% | 87.17% | 115.35% |
| Normalized Basic EPS | 76.50% | 13.09% | -85.98% | 77.51% | 13.00% |
| EPS Diluted | -26.19% | 13.28% | -81.82% | 86.20% | 112.77% |
| Normalized Diluted EPS | 75.44% | 12.75% | -86.09% | 75.82% | 11.85% |
| Average Basic Shares Outstanding | 2.20% | 2.25% | 2.22% | 1.68% | 1.72% |
| Average Diluted Shares Outstanding | 2.82% | 2.47% | 3.00% | 2.80% | 2.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |